| Literature DB >> 29510390 |
Cleo L Crunelle1,2, Wim van den Brink3, Franz Moggi4, Maija Konstenius5, Johan Franck5, Frances R Levin6, Geurt van de Glind7, Zsolt Demetrovics8, Corné Coetzee9, Mathias Luderer10, Arnt Schellekens11, Frieda Matthys1.
Abstract
Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity.Entities:
Keywords: Attention deficit/hyperactivity disorder; Consensus; Diagnosis; Substance use disorders; Treatment
Mesh:
Substances:
Year: 2018 PMID: 29510390 PMCID: PMC5986068 DOI: 10.1159/000487767
Source DB: PubMed Journal: Eur Addict Res ISSN: 1022-6877 Impact factor: 3.015